Podcasts about nmibc

  • 28PODCASTS
  • 81EPISODES
  • 51mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • May 30, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about nmibc

Latest podcast episodes about nmibc

AUAUniversity
Highlights from AUA2025: Advances in NMIBC (2025)

AUAUniversity

Play Episode Listen Later May 30, 2025 68:54


Highlights from AUA2025: Advances in NMIBC (2025) CME Available: https://auau.auanet.org/node/43167 At the conclusion of this CME activity, participants will be able to: 1. Recognize recent developments in the management of NMIBC. 2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events. 3. Employ current management approaches for NMIBC. 4. Utilize risk stratification to guide treatment decisions for NMIBC patients. 5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. This educational activity is supported by independent educational grants from: Merck & Co., Inc. ImmunityBio, Inc.

The EMJ Podcast: Insights For Healthcare Professionals
Bonus Episode: Adequate mitomycin C can effectively reduce recurrence and progression in patients with IR NMIBC – the value of maintenance therapy*

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later May 8, 2025 17:27


This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences. Topics discussed include: Current confusion about the clinical heterogeneity within the intermediate-risk patient group The best way to select adequate intravesical therapy for this group The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy *References Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/ Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.

The Uromigos
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC

The Uromigos

Play Episode Listen Later May 5, 2025 28:52


Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC

EAU Podcasts
AUA 2025 special: Dr. Neal Shore discusses phase 3 CREST study results

EAU Podcasts

Play Episode Listen Later May 3, 2025 12:11


At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC). Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.

OncLive® On Air
S12 Ep44: Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

OncLive® On Air

Play Episode Listen Later May 1, 2025 12:33


In today's episode, we had the pleasure of speaking with Jacob Moyer, BS, and Mark Tyson II, MD, MPH, about a real-world study investigating nadofaragene firadenovec in patients with BCG-unresponsive NMIBC. Moyer is a graduate researcher at Mayo Clinic in Scottsdale, Arizona. Tyson is a urologic oncologist and an associate professor of urology at the Mayo Clinic Alix School of Medicine in Arizona. In our exclusive interview, Moyer and Tyson discussed the durable responses achieved with nadofaragene firadenovec in this patient population, the safety profile of this agent, the importance of pretreatment with antispasmodic medication, and the optimal patient population to receive nadofaragene firadenovec.

Project Oncology®
First Results From Cohort 4 of the SunRISe-1 Trial

Project Oncology®

Play Episode Listen Later May 1, 2025


This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.

Project Oncology®
Trial in Progress: Phase 3 MoonRISe-3 Study

Project Oncology®

Play Episode Listen Later May 1, 2025


This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unresponsive high-risk NMIBC. He also covers the first results from cohort 4 of SunRISe-1, with a focus on papillary disease-only patients, along with the study design of the phase 3 MoonRISe-3 trial in patients with BCG-treated high-risk NMIBC and FGFR alterations. Each brief distills the clinical relevance of these studies and their potential impact on future NMIBC treatment strategies.

The Uromigos
Episode 410: AUA 2025 - BOND-003 Cohort C: Crestimogene in BCG-Unresponsive NMIBC

The Uromigos

Play Episode Listen Later Apr 27, 2025 29:08


Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC

The Uromigos
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC

The Uromigos

Play Episode Listen Later Apr 26, 2025 47:27


Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting

AUAUniversity
Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists

AUAUniversity

Play Episode Listen Later Dec 25, 2024 74:46


Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.

ACE OncoCast
Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (1 of 2)

ACE OncoCast

Play Episode Listen Later Nov 7, 2024 12:33


Félix Guerrero-Ramos, MD, PhD, FEBUHospital Doce de OctubreMadrid, SpainThe therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship', in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease.View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download.Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.

ACE OncoCast
Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (2 of 2)

ACE OncoCast

Play Episode Listen Later Nov 7, 2024 4:10


Natalia Carballo, MDMD Anderson Cancer Center MadridMadrid, SpainThe therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevance of different pathological subtypes of the disease and of the latest clinical evidence and guidelines that support the use of different therapies. These considerations were discussed in detail during the recent ‘Urothelial Cancer Preceptorship', in which experts in the field provided a detailed grounding of the disease process and management from diagnosis through to salvage treatments of advanced disease.View the Expert Interview on Specialist Insights in Urothelial Cancer from each faculty member which features specific expert insights on the topics related to the faculty presentations and the key questions discussed during the preceptorship. The enduring materials aimed to enable clinicians to integrate the latest advances and use of novel therapies for advanced urothelial cancer into safe and effective patient care. The presentation slides of the Preceptorship are also available to download.Based on the Expert Interview of Specialist Insights and Preceptorship held on 18 and 19 September 2024.

The Uromigos
Episode 360: The SUNRISE Program in Bladder Cancer

The Uromigos

Play Episode Listen Later Oct 15, 2024 46:19


Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

OncLive® On Air
S10 Ep50: Park and Grivas Expand on Treatment Updates in Bladder Cancer

OncLive® On Air

Play Episode Listen Later Aug 7, 2024 16:13


Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

BackTable Urology
Ep. 177 Latest Approaches to Treat High-Risk NMIBC with Dr. Ashish Kamat

BackTable Urology

Play Episode Listen Later Jul 9, 2024 54:21


In this episode of the BackTable Urology Podcast, Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena. --- CHECK OUT OUR SPONSOR Siemens Healthineers Theranostics https://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics --- SYNPOSIS Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat's expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine. --- TIMESTAMPS 00:00 - Introduction 03:56 - Initial Diagnosis and Workup 12:22 - High-Grade Bladder Cancer 22:37 - BCG and Alternative Treatments 31:30 - BCG Unresponsive Disease 36:56 - Novel Intravesical and Systemic Therapies 46:45 - Future Directions --- RESOURCES Related BackTable episodes: https://www.backtable.com/shows/urology/podcasts/64/management-of-bcg-refractory-nmibc https://www.backtable.com/shows/urology/podcasts/157/the-bladder-cancer-matters-podcast https://www.backtable.com/shows/urology/podcasts/103/adjuvant-therapy-for-high-risk-bladder-cancer

The Uromigos
Episode 331: AUA 2024 NMIBC Highlights

The Uromigos

Play Episode Listen Later Jun 21, 2024 33:56


Aditya Bagrodia describes three new drugs/studies in NMIBC.

AUAUniversity
AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems

AUAUniversity

Play Episode Listen Later Jun 19, 2024 112:18


AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems CME Available: https://auau.auanet.org/node/41097 At the conclusion of this activity, participants will be able to: 1. Implement current practice guidelines and explain methods and resources to improve TURBT skills. 2. Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage. 3. Identify methods to treat significant toxicities from various intravesical therapies. 4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease. 5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Merck & Co., Inc.

BackTable Urology
Ep. 172 Advancing Cancer Care: AUA 2024 Highlights in Prostate and Bladder Cancer with Dr. Jeff Tosoian and Dr. Woodson Smelser

BackTable Urology

Play Episode Listen Later Jun 18, 2024 44:05


In this episode of the BackTable Urology, Dr. Bogdana Schmidt (University of Utah), Dr. Woodson Smelser (Washington University in St. Louis), and Dr. Jeff Tosoian (Vanderbilt University) discusses the latest insights and advancements in prostate and bladder cancer treatment presented at AUA 2024. --- CHECK OUT OUR SPONSOR Veracyte https://www.veracyte.com/decipher --- SYNPOSIS First, the doctors cover noteworthy topics, including the effectiveness of early screening and treatment for high-risk prostate cancer patients, innovative approaches in imaging and biomarkers, and the impact of new guidelines on salvage therapy. They also explore emerging treatments for non-muscle invasive bladder cancer (NMIBC), as well as the evolving role of systemic immunotherapies and advanced genomic testing. To wrap up, the urologists offer detailed analyses and their expert opinions on how these developments could transform patient care in the field of urologic oncology. --- TIMESTAMPS 00:00 - Introductions 03:06 - Prostate Cancer Screening Insights 10:10 - Advancements in MRI and Biomarkers 18:22 - Transperineal vs. Transrectal Prostate Biopsy 27:18 - New Guidelines for Bladder Cancer Treatment 30:57 - Innovative Drug Delivery Systems 32:36 - Gene Therapy and Immunotherapy Advances 40:11 - Concluding Thoughts and Future Prospects --- RESOURCES Decipher Prostate Genomic Classifier by Veracyte: ​​https://decipherbio.com/decipher-prostate/physicians/decipher-prostate-overview/

Research To Practice | Oncology Videos
Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer'

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 18, 2024 83:27


Featuring perspectives from Dr Petros Grivas, including the following topics: Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00) Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16) Perspective on recurrence mechanisms of NMIBC (22:21) Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27) Importance of collaborative care for patients with bladder cancer (42:02) Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57) Monitoring and management of T-DXd-associated side effects (1:00:47) Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32) Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22) Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer's disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12) CME information and select publications

The Uromigos
Episode 317: AUA 2024 Preview with the AUA Secretary

The Uromigos

Play Episode Listen Later May 1, 2024 22:16


David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.

Business Of Biotech
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.

Business Of Biotech

Play Episode Listen Later Apr 15, 2024 56:54 Transcription Available


This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate, Anktiva, nears the goal line in non-muscle invasive bladder cancer (NMIBC). From grassroots engagement with physicians and urologists to making a global press to share clinical results, Dr. Reddy offers plenty of insight into biopharma commercial readiness, and good reason to hope for nearly a million NMIBC patients in the U.S. alone. You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Adis Journal Podcasts
The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast

Adis Journal Podcasts

Play Episode Listen Later Feb 2, 2024 35:25


This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-023-02763-z. All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

AUAUniversity
Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer

AUAUniversity

Play Episode Listen Later Dec 18, 2023 40:35


The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer CME Available: https://auau.auanet.org/node/39374 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC. 2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions. 3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merck & Co., Inc.

EAU Podcasts
Prof. James Catto (GB) shares results of THOR-2 cohort 1 study

EAU Podcasts

Play Episode Listen Later Nov 12, 2023 7:26


In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. James Catto (GB) about the THOR-2 cohort 1 study: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment. Prof. Catto shares details on the rationale and design of the THOR-2 cohort 1 study, the results he presented at ESMO 2023, and some important take-home messages. For more details on this study, you can read this abstract on the UROONCO Bladder Cancer educational platform.

Oncology Brothers
ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore

Oncology Brothers

Play Episode Listen Later Nov 6, 2023 13:06


In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay: - SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG - with TAR-200 mono therapy achieving 77% overall complete response rate - EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed impressive PFS and OS - PSMAfore – 177Lu-PSMA-617 Versus Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer with impressive responsiveness

The Uromigos
Episode 277: NMIBC Discussion at #UromigosLive 2023

The Uromigos

Play Episode Listen Later Nov 4, 2023 43:50


Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

ACE OncoCast
Expert Interview: Frequently Asked Questions (FAQs) for Non Muscle Invasive Bladder Cancer (NMIBC)

ACE OncoCast

Play Episode Listen Later Nov 3, 2023 7:22 Transcription Available


About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunotherapy with bacille Calmette-Guérin (BCG) or intravesical chemotherapy (mitomycin C, epirubicin, or doxorubicin). The decision to instill BCG and/or chemotherapy is based on the risk of cancer progression or recurrence.For practicing oncologists, it is crucial to address Frequently Asked Questions (FAQs) regarding NMIBC such as how to define individual risk groups and treatment recommendations for each group, how to identify BCG refractoriness and relapse in clinical practice, and how to manage patients who are BCG refractory. Let's watch the recorded video on 'Frequently Asked Questions (FAQs) for NMIBC' to gain comprehensive insights from leading experts – Dr. Francisco X. Real from National Cancer Research Center of Spain and Dr. Félix Guerrero Ramos from Hospital Universitario 12 de Octubre in Madrid, Spain.

The EMJ Podcast: Insights For Healthcare Professionals
Bonus Episode: A podcast exploring the DaBlaCa-13 study, chemoresection with dose-dense mitomycin C (MMC) in patients with recurrent non-muscle-invasive bladder cancer (intermediate-risk)

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Oct 23, 2023 17:31


Tune in for a fascinating discussion with Jørgen Bjerggaard Jensen, Department of Urology, Aarhus University, Denmark, as he explores recent breakthroughs in non-muscle-invasive bladder cancer (NMIBC) management through mitomycin C (MMC) chemoresection. Jensen addresses the critical need to advance NMIBC management, underscoring its unique status as a disease of field cancerisation. Delving into the study's main findings, Jensen discusses the efficacy of MMC chemoresection and the potential effectiveness in both low-grade and high-grade Ta tumours. Safety and tolerability aspects are also examined, highlighting the promise this intervention holds for patients and urologists alike. This content was funded by medac GmbH.

Oncology Today with Dr Neil Love
Special Edition — Management of Urothelial Bladder Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Jul 21, 2023 56:37


Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (http://www.ResearchToPractice.com/ASCO2023Bladder/AudioInterview)

Oncology Today with Dr Neil Love
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder Cancer

Oncology Today with Dr Neil Love

Play Episode Listen Later Jul 20, 2023 52:14


Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer. CME information and select publications here (https://www.researchtopractice.com/ONS2023Bladder/Audiointerview)

AUAUniversity
Global Advancements in Bladder Cancer

AUAUniversity

Play Episode Listen Later Jun 21, 2023 77:35


Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed. CME Available: https://auau.auanet.org/node/38615 ACKNOWLEDGEMENTS This educational series is supported by an independent educational grant from AstraZeneca. After participating in this educational series, participants will be able to: 1. Delineate key factors to risk stratify patients with NMIBC and MIBC. 2. Review guidelines focused on first‐ and second‐line therapies for NMIBC and MIBC. 3. Describe emerging treatment options with intravesical and systemic therapies for patients in an era of BCG shortage and for patients with BCG unresponsive disease and determine the appropriate timing and use of neoadjuvant and adjuvant systemic therapy for invasive bladder cancer. 4. Identify side effects and possible interventions to ameliorate side effects for these therapies. 5. Recognize the urologist's role in clinical trials and how to overcome obstacles to clinical trial enrollment.

EAU Podcasts
SunRISe-1 results: Interview with Prof. Daneshmand at AUA2023

EAU Podcasts

Play Episode Listen Later May 9, 2023 13:23


In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Siamak Daneshmand (US) from the Keck School of Medicine, University of Southern California. Prof. Daneshmand answers questions about the SunRISe-1 trial, which he presented at the 'late-breaking oncology abstract session' during AUA2023. He discusses the study design, and delivers preliminary results from SunRISe-1 in patients with BCG (Bacillus Calmette-Guérin) unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone. The promising findings from TAR-200 monotherapy showed an overall complete response rate of 73% in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who were unresponsive to BCG. Prof. Daneshmand says the treatment was well-tolerated. Additionally, cetrelimab monotherapy demonstrated safety and efficacy profiles consistent with other anti-PD-L1 treatments in this disease setting.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 18, 2023 62:18


Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 18, 2023 62:32


Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 18, 2023 62:32


Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 18, 2023 62:18


Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 18, 2023 62:18


Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Apr 18, 2023 62:32


Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

The Uromigos
Episode 230: FGFR inhibition in NMIBC

The Uromigos

Play Episode Listen Later Mar 28, 2023 26:03


Sia Daneshmand describes two prospective studies with erdafitinib in NMIBC.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 88:55


Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 28, 2023 88:44


Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 28, 2023 88:44


Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 88:55


Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 88:55


Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

PeerView Clinical Pharmacology CME/CNE/CPE Video
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Mar 28, 2023 88:44


Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

The Uromigos
Episode 223: #ASCOGU23 Pembrolizumab in papillary NMIBC

The Uromigos

Play Episode Listen Later Feb 17, 2023 24:27


Andrea Necchi discusses the papillary cohort of KN57

FRCS UROCAST
Episode 2: High Risk Non-Muscle Invasive Bladder Cancer (with Will Green)

FRCS UROCAST

Play Episode Listen Later Feb 6, 2023 31:23


In our second episode, we are joined by Will Green, Consultant Urologist from Nottingham, to talk about the management of high-risk NMIBC.  We tackle important questions such as who should have BCG (and does it work?) and which patients are suitable for primary cystectomy.Hosts: Sophia Cashman and Hari Ratan

OncLive® On Air
S8 Ep17: FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

OncLive® On Air

Play Episode Listen Later Jan 26, 2023 12:55


Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy's administration method and schedule, and how this agent's efficacy and safety pave the way for future treatment advances.

The Uromigos
Episode 213: IL-15RaFc superagonist in NMIBC

The Uromigos

Play Episode Listen Later Jan 9, 2023 23:27


Sam Chang describes the data for this agent in bladder cancer. 

BackTable Urology
Ep. 64 Management of BCG-refractory NMIBC with Dr. Timothy Clinton and Dr. Eugene Pietzak

BackTable Urology

Play Episode Listen Later Nov 9, 2022 55:33


The EMJ Podcast: Insights For Healthcare Professionals
How to Optimise Adjuvant Intravesical Chemotherapy for Patients with Intermediate-Risk NMIBC

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Nov 7, 2022 9:05


This episode of the EMJ podcast delves into treatment options for patients with intermediate-risk (IR) non-muscle invasive bladder cancer (NMIBC). With a wide range of subgroups that patients with IR NMIBC can fit into, there are many challenges associated with selecting optimal treatment options. Rodolfo Hurle, Chief of the Bladder Unit at IRCCS Humanitas Research Hospital, Milan, Italy, offers his expert perspective on this pertinent topic, as well as insights into the current standard-of-care for patients with IR NMIBC. Highlighting the risk factors that need to be taken into consideration during the substratification of patients with IR NMIBC, Hurle explains the different approaches to treatment, as well as the duration of maintenance instillations. The potential roles of chemohyperthermia and neoadjuvant therapy for patients with IR NMIBC are explored, with Hurle providing key takeaway insights to listeners.

Research To Practice | Oncology Videos
Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Nonmetastatic Urothelial Bladder Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Oct 20, 2022 46:18


Featuring an interview with Prof Sia Daneshmand, including the following topics: Clinical presentation and initial evaluation of non-muscle-invasive urothelial bladder cancer (NMIBC) (0:00) Alternative induction regimens when BCG is not available (4:06) Treatment options for patients with BCG-refractory disease (8:46) Role of immunotherapy in treating NMIBC (13:58) Role of cystectomy in treating NMIBC (15:47) Intravesical drug delivery for patients with muscle-invasive urothelial bladder cancer (MIBC) (20:37) Dispelling myths and misperceptions about cystectomy and counseling eligible patients (26:19) Neoadjuvant and adjuvant therapy for MIBC (37:40) CME information and select publications

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 22, 2022 60:38


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 22, 2022 60:29


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 22, 2022 60:29


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 22, 2022 60:29


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 22, 2022 60:38


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 22, 2022 60:38


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 22, 2022 60:38


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 22, 2022 60:29


Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Better Edge : A Northwestern Medicine podcast for physicians
Update on First Biomarker-Directed Trial of Non-Muscle-Invasive Bladder Cancer

Better Edge : A Northwestern Medicine podcast for physicians

Play Episode Listen Later Jul 20, 2022


Erdafitinib (balversa), an oral pan-fibroblast growth factor receptor (FGFR) 1-4 inhibitor, is being used in one of the first biomarker-directed trials of high-risk non-muscle-invasive bladder cancer (NMIBC). The Thor-2 trial (NCT04172675) targets tumors with driver mutations in the FGFR3 gene. This gene is altered in 40% to 70% of early-stage bladder cancers and may be a rare driver mutation in bladder cancer. If successful, Erdafitinib would the first precision therapy for early stage bladder cancer. In this podcast episode, lead investigator Joshua J. Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD Professor of Urology and associate professor of Urology and of Biochemistry and Molecular Genetics at Northwestern Medicine, explains the Thor-2 trial and how it could be a new paradigm in bladder oncology. Disclosure Statement:Joshua J. Meeks, MD, PhD has received consulting-related fees from Janssen.

AUAUniversity
AUA2022: Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach

AUAUniversity

Play Episode Listen Later Jun 15, 2022 114:32


Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach (2022) CME Available: https://auau.auanet.org/node/36020 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Identify low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC) 2. Recommend treatment for NMIBC based on risk stratification. 3. Identify bacillus Calmette-Guérin (BCG) unresponsive NMIBC and novel immune-based strategies and intravesical therapies. 4. Manage invasive bladder cancer including surgery, neoadjuvant and adjuvant chemotherapy and bladder preservation strategies in patients with muscle invasive bladder cancer. This will include chemotherapy indications and the role of immunotherapy in the management. 5. Manage upper tract tumors, both low grade and high grade, including renal preservation when appropriate, neoadjuvant therapy when indicated and surgical management strategies.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 14, 2022 81:08


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 14, 2022 81:08


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 14, 2022 81:08


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 14, 2022 81:08


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 14, 2022 81:18


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 14, 2022 81:08


Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

Research To Practice | Oncology Videos
Kidney and Bladder Cancer | Proceedings From Our Year in Review Webinar on Kidney and Bladder Cancer

Research To Practice | Oncology Videos

Play Episode Listen Later Mar 24, 2022 64:10


Featuring perspectives from Dr Elizabeth Plimack and Prof Thomas Powles, including the following topics: Advances in Renal Cell Carcinoma — Thomas Powles, MBBS, MRCP, MD  Introduction (0:00) Adjuvant Therapy in Renal Cell Carcinoma (RCC) (8:05) First-Line Treatment of Metastatic RCC (15:16) Belzutifan for von Hippel-Lindau-Associated RCC (29:38) Non-Clear Cell RCC (34:57) Urothelial Bladder Carcinoma — Elizabeth R Plimack, MD, MS Non-Muscle-Invasive Bladder Cancer (NMIBC) (37:47) Adjuvant and Neoadjuvant Treatments for NMIBC (44:38) Sequencing Therapies for Metastatic Urothelial Bladder Cancer (57:54) CME information and select publications

EMPIRE Urology Podcast
#029 High Risk nMIBC in the era of BCG Shortage

EMPIRE Urology Podcast

Play Episode Listen Later Sep 18, 2021 51:32


Dr. Gary Steinberg MD discusses the management of high risk non-muscle invasive bladder cancer in the era of BCG shortage 5/5/20

EMPIRE Urology Podcast
#011 Risk Stratified Management of nMIBC

EMPIRE Urology Podcast

Play Episode Listen Later Sep 9, 2021 57:30


Dr Manish Vira MD discusses Risk stratified management of non muscle invasive bladder cancer 4/21/2020

AUAUniversity
NMIBC Guidelines

AUAUniversity

Play Episode Listen Later Sep 3, 2021 32:21


NMIBC Guidelines by AUAUniversity

Katheterkollegen - der Urologie Podcast
Von Elektroswing und Elektroschlingen - das NMIBC

Katheterkollegen - der Urologie Podcast

Play Episode Listen Later Aug 29, 2021 53:34


Anlass zu dieser Folge war ein Hörerwunsch! Die Katheterkollegen befassen sich dieses Mal mit dem nicht-muskelinvasiven Harnblasenkarzinom. Dr. Hannah Arnold und Prof. Mario Kramer erklären alles von Photodynamischer Diagnostik bis zu high-risk und highest-risk Karzinomen, Nachsorge und Therapieverläufen. Viel Spaß beim Anhören wünschen eure Katheterkollegen! Bladder Calculator: https://nmibc.net

The EMJ Podcast: Insights For Healthcare Professionals
Bonus Episode: Benefits of Neoadjuvant use of Mitomycin C for the Management of NMIBC

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later May 13, 2021 29:48


This episode, sponsored by medac, is a discussion around non-muscle-invasive bladder cancer (NMIBC). We hear from Professor Jørgen Bjerggaard Jensen, who leads clinical research in bladder cancer at the Department of Urology, Aarhus University Hospital, as he explores the management of NMIBC through the neoadjuvant use of Mitomycin C (MMC).

The Uromigos
Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC

The Uromigos

Play Episode Listen Later Feb 6, 2021 17:21


Stephen Boorjian outlines his recent Lancet oncology paper. Tom and Brian struggle to keep up.

The Uromigos
Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC

The Uromigos

Play Episode Listen Later Jun 16, 2020 20:21


Peter Black talks about his recent BCG refractory NMIBC ASCO presentation and its implications for the field.

The Rx Daily Dose
Episode 16 - Fiasp, Keytruda & HR5534

The Rx Daily Dose

Play Episode Listen Later Jan 10, 2020 11:39


Here are the links for everything discussed in Episode 16. Added indication for Fiasp in pediatrics Keytruda expanded to include BCG-unresponsive NMIBC with CIS FDA warns generic manufacturers to follow the law HR5534 is introduced into legislation Connect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★